No Influence on Cardiac Arrhythmia or Heart Rate from Long-Term Treatment with Tiotropium/Olodaterol versus Monocomponents by Holter ECG Analysis in Patients with Moderate-to-Very-Severe COPD

References

• FearyJR, RodriguesLC, SmithCJ, HubbardRB, GibsonJE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010;65(11):956–962. doi:10.1136/thx.2009.12808220871122
   PubMed Web of Science ®Google Scholar
• VogelmeierCF, CrinerGJ, MartinezFJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–582. doi:10.1164/rccm.201701-0218PP28128970
   PubMed Web of Science ®Google Scholar
• CazzolaM, CalzettaL, BettoncelliG, et al. Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study. Respir Med. 2012;106(2):249–256. doi:10.1016/j.rmed.2011.07.02121856140
   PubMed Web of Science ®Google Scholar
• HawkinsNM, PetrieMC, MacdonaldMR, et al. Heart failure and chronic obstructive pulmonary disease the quandary of beta-blockers and beta-agonists. J Am Coll Cardiol. 2011;57(21):2127–2138. doi:10.1016/j.jacc.2011.02.02021596228
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim International GmbH. Striverdi Respimat 2.5 microgram, solution for inhalation – Summary of Product Characteristics, Europe; 2019 Available from: https://www.medicines.org.uk/emc/product/3255/smpc. Accessed 124, 2019.
   Google Scholar
• Boehringer Ingelheim International GmbH. Spiriva® Respimat® 2.5 microgram, solution for inhalation – Summary of Product Characteristics, Europe; 2016 Available from: https://www.spiriva.com/uk/sites/default/files/Spiriva%20Respimat%20SPC%20(1).pdf. Accessed 116, 2019.
   Google Scholar
• TashkinDP, CelliB, SennS, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554. doi:10.1056/NEJMoa080580018836213
   PubMed Web of Science ®Google Scholar
• O’DonnellDE, FlugeT, GerkenF, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23(6):832–840. doi:10.1183/09031936.04.0011600415218994
   PubMed Web of Science ®Google Scholar
• WiseRA, AnzuetoA, CottonD, et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013;369(16):1491–1501. doi:10.1056/NEJMoa130334223992515
   PubMed Web of Science ®Google Scholar
• AnzuetoA, WiseR, CalverleyP, et al. The tiotropium safety and performance in Respimat® (TIOSPIR®) trial: spirometry outcomes. Respir Res. 2015;16:107. doi:10.1186/s12931-015-0269-426369563
   PubMed Web of Science ®Google Scholar
• McGarveyL, NiewoehnerD, MagderS, et al. One-year safety of olodaterol once daily via Respimat® in patients with GOLD 2-4 chronic obstructive pulmonary disease: results of a pre-specified pooled analysis. COPD. 2015;12(5):484–493. doi:10.3109/15412555.2014.99186425692310
   PubMedGoogle Scholar
• FergusonGT, FeldmanGJ, HofbauerP, et al. Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014;9:629–645. doi:10.2147/COPD.S6171724966672
   PubMed Web of Science ®Google Scholar
• KochA, PizzichiniE, HamiltonA, et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014;9:697–714. doi:10.2147/COPD.S6250225045258
   PubMed Web of Science ®Google Scholar
• KochA, WatzH, Maleki-YazdiMR, et al. Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2-agonist formoterol. NPJ Prim Care Respir Med. 2017;27(1):60. doi:10.1038/s41533-017-0059-129061968
   PubMed Web of Science ®Google Scholar
• AndreasS, BothnerU, TrampischM, HaenselM, BuhlR, AlterP. Effect of long-acting β2-agonists olodaterol and formoterol on heart rate and blood pressure in chronic obstructive pulmonary disease patients. Pulm Pharmacol Ther. 2018;52:1–6. doi:10.1016/j.pupt.2018.08.00230077810
   PubMed Web of Science ®Google Scholar
• SinghD, FergusonGT, BolitschekJ, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015;109(10):1312–1319. doi:10.1016/j.rmed.2015.08.00226320402
   PubMed Web of Science ®Google Scholar
• SinghD, GagaM, SchmidtO, et al. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies. Respir Res. 2016;17(1):73. doi:10.1186/s12931-016-0387-727316465
   PubMed Web of Science ®Google Scholar
• BeehKM, WestermanJ, KirstenAM, et al. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2015;32:53–59. doi:10.1016/j.pupt.2015.04.00225956072
   PubMed Web of Science ®Google Scholar
• MaltaisF, HamiltonA, VossF, Maleki-YazdiMR. Dose determination for a fixed-dose drug combination: a Phase II randomized controlled trial for tiotropium/olodaterol versus tiotropium in patients with COPD. Adv Ther. 2019;36(4):962–968. doi:10.1007/s12325-019-00911-y30843141
   PubMed Web of Science ®Google Scholar
• LahousseL, VerhammeKM, StrickerBH, BrusselleGG. Cardiac effects of current treatments of chronic obstructive pulmonary disease. Lancet Respir Med. 2016;4(2):149–164. doi:10.1016/S2213-2600(15)00518-426794033
   PubMed Web of Science ®Google Scholar
• SinghS, LokeYK, EnrightPL, FurbergCD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ. 2011;342:d3215. doi:10.1136/bmj.d321521672999
   PubMed Web of Science ®Google Scholar
• SinghS, LokeYK, FurbergCD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(12):1439–1450. doi:10.1001/jama.300.12.143918812535
   PubMed Web of Science ®Google Scholar
• AndreasS, BothnerU, de la HozA, KloerI, TrampischM, AlterP. A post hoc Holter ECG analysis of olodaterol and formoterol in moderate-to-very-severe COPD Int J Chron Obstruct Pulmon Dis. In press 2020.
   Google Scholar
• HohlfeldJM, FurtwaenglerA, Konen-BergmannM, WallensteinG, WalterB, BatemanED. Cardiac safety of tiotropium in patients with COPD: a combined analysis of Holter-ECG data from four randomised clinical trials. Int J Clin Pract. 2015;69(1):72–80.25496316
   PubMed Web of Science ®Google Scholar
• HalpinDM, DahlR, HallmannC, MuellerA, TashkinD. Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis. Int J Chron Obstruct Pulmon Dis. 2015;10:239–259. doi:10.2147/COPD.S7514625709423
   PubMed Web of Science ®Google Scholar
• BuhlR, MagderS, BothnerU, et al. Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease. Respir Med. 2017;122:58–66. doi:10.1016/j.rmed.2016.11.01127993292
   PubMed Web of Science ®Google Scholar
• KarnerC, ChongJ, PooleP. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;11(7):CD009285.
   Google Scholar
• DongYH, LinHH, ShauWY, WuYC, ChangCH, LaiMS. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax. 2013;68(1):48–56. doi:10.1136/thoraxjnl-2012-20192623042705
   PubMed Web of Science ®Google Scholar
• SuissaS, Dell’AnielloS, ErnstP. Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events. Eur Respir J. 2017;49(5):1602245. doi:10.1183/13993003.02245-201628536251
   PubMed Web of Science ®Google Scholar
• CazzolaM, ImperatoreF, SalzilloA, et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest. 1998;114(2):411–415. doi:10.1378/chest.114.2.4119726723
   PubMed Web of Science ®Google Scholar
• HaarmannH, MohrlangC, TschiesnerU, et al. Inhaled β-agonist does not modify sympathetic activity in patients with COPD. BMC Pulm Med. 2015;15:46. doi:10.1186/s12890-015-0054-725924990
   PubMed Web of Science ®Google Scholar
• FergusonGT, Funck-BrentanoC, FischerT, DarkenP, ReisnerC. Cardiovascular safety of salmeterol in COPD. Chest. 2003;123(6):1817–1824. doi:10.1378/chest.123.6.181712796155
   PubMed Web of Science ®Google Scholar
• GalliA, AmbrosiniF, LombardiF. Holter monitoring and loop recorders: from research to clinical practice. Arrhythm Electrophysiol Rev. 2016;5(2):136–143. doi:10.15420/AER.2016.17.227617093
   PubMedGoogle Scholar
• BuhlR, MaltaisF, AbrahamsR, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J. 2015;45(4):969–979. doi:10.1183/09031936.0013601425573406
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Pocket guide to COPD diagnosis, management and prevention – A guide for health care professionals (2019report); 2019 Available from: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-POCKET-GUIDE-FINAL_WMS.pdf. Accessed 1219, 2019.
   Google Scholar
• FergusonGT, BuhlR, BothnerU, et al. Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials. Respir Med. 2018;143:67–73. doi:10.1016/j.rmed.2018.08.01230261995
   PubMed Web of Science ®Google Scholar
• HandleyDA, MorleyJ. The pursuit of precision pharmaceuticals: divergent effects of β2 agonist isomers. Expert Opin Investig Drugs. 1998;7(10):1601–1616. doi:10.1517/13543784.7.10.1601
   PubMedGoogle Scholar
• RamsayCM, CowanJ, FlanneryE, McLachlanC, TaylorDR. Bronchoprotective and bronchodilator effects of single doses of (S)-salbutamol, (R)-salbutamol and racemic salbutamol in patients with bronchial asthma. Eur J Clin Pharmacol. 1999;55(5):353–359. doi:10.1007/s00228005064010456484
   PubMed Web of Science ®Google Scholar
• LötvallJ, PalmqvistM, AnkerstJ, et al. The effect of formoterol over 24h in patients with asthma: the role of enantiomers. Pulm Pharmacol Ther. 2005;18(2):109–113. doi:10.1016/j.pupt.2004.10.00715649853
   PubMed Web of Science ®Google Scholar
• TerasakiJ, NishiS, AmeredesB, SharmaG. Arformoterol: rationale for use in chronic obstructive pulmonary disease. Clin Investig (Lond). 2014;4:429–439.
   Google Scholar
• AndreasS, McGarveyL, BothnerU, et al. Absence of adverse effects of tiotropium/olodaterol compared with the monocomponents on long-term heart rate and blood pressure in patients with moderate-to-very-severe COPD. Int J Chron Obstruct Pulmon Dis.  In press 2020.
   Google Scholar
• AndreasS, AnkerSD, ScanlonPD, SomersVK. Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest. 2005;128(5):3618–3624. doi:10.1378/chest.128.5.361816304321
   PubMed Web of Science ®Google Scholar
• AndreasS, HaarmannH, KlarnerS, HasenfussG, RaupachT. Increased sympathetic nerve activity in COPD is associated with morbidity and mortality. Lung. 2014;192(2):235–241. doi:10.1007/s00408-013-9544-724362752
   PubMed Web of Science ®Google Scholar
• ByrdJB, NewbyDE, AndersonJA, et al. Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial. Eur Heart J. 2018;39(33):3128–3134. doi:10.1093/eurheartj/ehy45130101300
   PubMed Web of Science ®Google Scholar
• HuiartL, ErnstP, SuissaS. Cardiovascular morbidity and mortality in COPD. Chest. 2005;128(4):2640–2646. doi:10.1378/chest.128.4.264016236937
   PubMed Web of Science ®Google Scholar
• FuhrmanC, JouglaE, NicolauJ, EilsteinD, DelmasMC. Deaths from chronic obstructive pulmonary disease in France, 1979–2002: a multiple cause analysis. Thorax. 2006;61(11):930–934. doi:10.1136/thx.2006.06126716738039
   PubMed Web of Science ®Google Scholar
• JensenMT, SuadicaniP, HeinHO, GyntelbergF. Elevated resting heart rate, physical fitness and all-cause mortality: a 16-year follow-up in the Copenhagen Male Study. Heart. 2013;99(12):882–887. doi:10.1136/heartjnl-2012-30337523595657
   PubMed Web of Science ®Google Scholar
• SchrierRW, AbrahamWT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341(8):577–585. doi:10.1056/NEJM19990819341080610451464
   PubMed Web of Science ®Google Scholar